BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32726136)

  • 1. Validation of a Highly Sensitive qPCR Assay for the Detection of Plasma Cell-Free Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma Diagnosis.
    Anh VNQ; Van Ba N; Anh DT; Ung ND; Hiep NH; Ly VT; Hang DTT; Sy BT; Chinh HD; Ky LM; Phong VT; Luu NK; Trung NT; Son HA; Van Luong H; Thuan ND; Tung NT; Tho HH
    Cancer Control; 2020; 27(3):1073274820944286. PubMed ID: 32726136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
    Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
    BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort.
    Tay JK; Siow CH; Goh HL; Lim CM; Hsu PP; Chan SH; Loh KS
    Int J Cancer; 2020 May; 146(10):2923-2931. PubMed ID: 31705522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
    Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
    Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trans-oral brush biopsies and quantitative PCR for EBV DNA detection and screening of nasopharyngeal carcinoma.
    Ng RH; Ngan R; Wei WI; Gullane PJ; Phillips J
    Otolaryngol Head Neck Surg; 2014 Apr; 150(4):602-9. PubMed ID: 24486777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with nasopharyngeal carcinoma.
    Gao W; Wong TS; Lv KX; Zhang MJ; Tsang RK; Chan JY
    Head Neck; 2019 Mar; 41(3):780-792. PubMed ID: 30548946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China.
    Chen H; Chen S; Lu J; Wang X; Li J; Li L; Fu J; Scheper T; Meyer W; Peng YH; Liu W
    Cancer Prev Res (Phila); 2017 Sep; 10(9):542-550. PubMed ID: 28754665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region.
    Pramanik R; Arora S; Sharma P; Biswas A; Nayak B; Thakar A; Sharma A; Ghose S
    J Med Virol; 2022 Feb; 94(2):720-728. PubMed ID: 34750844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
    Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
    Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
    Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma.
    Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS;
    Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of nasal and nasopharyngeal swab collection for the detection of Epstein-Barr virus in nasopharyngeal carcinoma.
    Coghill AE; Wang CP; Verkuijilen SAWM; Yu KJ; Hsu WL; Middeldorp JM; Hildesheim A
    J Med Virol; 2018 Jan; 90(1):191-195. PubMed ID: 28833336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma.
    Tan GW; Sivanesan VM; Abdul Rahman FI; Hassan F; Hasbullah HH; Ng CC; Khoo AS; Tan LP
    Int J Cancer; 2019 Oct; 145(8):2260-2266. PubMed ID: 30698824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma.
    Tan R; Phua SKA; Soong YL; Oon LLE; Chan KS; Lucky SS; Mong J; Tan MH; Lim CM
    Cancer Commun (Lond); 2020 Nov; 40(11):564-585. PubMed ID: 32989921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-free Epstein-Barr virus-DNA in patients with nasopharyngeal carcinoma: Plasma versus urine.
    Sengar M; Chorghe S; Jadhav K; Singh S; Laskar SG; Pai P; Aggarwal JP; D'Cruz A; Chaturvedi P; Deshpande M; Chaukar D; Budrukkar A; Gupta T; Murthy V; Kane S; Thakur M; Rangarajan V; Kannan S; Shet T; Kode J
    Head Neck; 2016 Apr; 38 Suppl 1():E1666-73. PubMed ID: 26667883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation.
    Peng L; Yang Y; Guo R; Mao YP; Xu C; Chen YP; Sun Y; Ma J; Tang LL
    Cancer Med; 2018 Dec; 7(12):5988-5998. PubMed ID: 30378277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.